billions from deceptions that “Suboxone Film was safer, less divertible, and less abusable”

From Bloomberg: Indivior misled doctors and government health programs into believing that the drug, Suboxone Film, was safer and less likely to be abused than rivals, the Justice Department said in a statement Tuesday. . . . Federal prosecutors in the Western District of Virginia said Indivior’s deceptions had contributed to an epidemic that has … Continue reading billions from deceptions that “Suboxone Film was safer, less divertible, and less abusable”

Hazelden shares rationale for Suboxone over methadone

Hazelden just sent a newsletter that included a teaser about the rationale for their adoption of Suboxone over methadone. It links to this article that describes their reasoning this way: We found that buprenorphine was a better medication for our patient population and our goals of transitional use of MAT versus long-term medication maintenance. While methadone … Continue reading Hazelden shares rationale for Suboxone over methadone

“nothing was quite like Suboxone”

There have been a couple of news stories about buprenorphine over the last couple of days. The first article looks at the business of pain medication, medications to treat side effects of pain medication and medications to treat addiction to pain medication. Opioid prescriptions alone have skyrocketed from 112 million in 1992 to nearly 249 … Continue reading “nothing was quite like Suboxone”

Buprenorphine Outpatient Outcomes Project

I recently came across this 2014 study of 220 buprenorphine patients. I mentioned it in another post and noted this sentence from the conclusion as underwhelming, “The number of legal charges for drug possession decreased from 70 to 62.” Turns out that this sentence casts their outcomes in a misleadingly positive light. In the year … Continue reading Buprenorphine Outpatient Outcomes Project

Pediatric use of buprenorphine has a piece advocating more use of buprenorphine with children. Medication-Assisted Treatment (MAT) for opioid dependence is a science-based and proven-effective option for teens and young adults. It should be administered with age appropriate psychosocial therapy and drug testing. Unfortunately, it has been subject to controversy and stigma. Yet the neuroscience of addiction and … Continue reading Pediatric use of buprenorphine

Two more defenses of Suboxone

In the Washington Post, Harold Pollack interviewed Peter Friedmann about buprenorphine and the NY Times series on buprenorphine. We’re fortunate that that they share their premises. HP: Buprenorphine provides a “substitution therapy” for people with opiate disorders. PF: Correct. For many years, opiate addiction was considered an incurable illness. It was Dole and Nyswander in New York who proposed … Continue reading Two more defenses of Suboxone

NY Times / Suboxone redux

  I thought I was done, but here are a couple more smart takes. Both support maintenance but appreciate the article raising awareness of important problems.   From The Institute Blog:   And as the articles (and the comment section) demonstrate, the use of buprenorphine to treat addiction and prevent substance use-related harms is messy.  Interlacing text and video, … Continue reading NY Times / Suboxone redux

Suboxone diversion?

A recent study looking at diversion of buprenorphine finds that: While 9% reported recent street-obtained buprenorphine use, only a small minority reported using buprenorphine to get high, with the majority reporting use to manage withdrawal symptoms. The use of street-obtained buprenorphine primarily to avoid withdrawal fits with Dawn Farm’s experience, though the percentage would be … Continue reading Suboxone diversion?